COH – Credit Suisse rates as Underperform

By Broker News | More Articles by Broker News

The US FDA has approved the company’s Nucleus Hybrid L24 implant. This is the first implantable device approved by the FDA for a specific indication. Credit Suisse observes this is a sizeable market opportunity but there is a risk of low-frequency hearing loss, which may limit the market penetration of the device.

The Underperform rating and $51.10 target are maintained.

Sector: Health Care Equipment & Services.

Target price is $51.10.Current Price is $58.96. Difference: ($7.86) – (brackets indicate current price is over target). If COH meets the Credit Suisse target it will return approximately -15% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →